320 related articles for article (PubMed ID: 26645190)
21. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ; Reni M; Foppoli M; Martelli M; Pangalis GA; Frezzato M; Cabras MG; Fabbri A; Corazzelli G; Ilariucci F; Rossi G; Soffietti R; Stelitano C; Vallisa D; Zaja F; Zoppegno L; Aondio GM; Avvisati G; Balzarotti M; Brandes AA; Fajardo J; Gomez H; Guarini A; Pinotti G; Rigacci L; Uhlmann C; Picozzi P; Vezzulli P; Ponzoni M; Zucca E; Caligaris-Cappio F; Cavalli F;
Lancet; 2009 Oct; 374(9700):1512-20. PubMed ID: 19767089
[TBL] [Abstract][Full Text] [Related]
22. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
23. WITHDRAWN: Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.
Choy EH; Hoogendijk JE; Lecky B; Winer JB; Gordon P
Cochrane Database Syst Rev; 2009 Oct; (4):CD003643. PubMed ID: 19821312
[TBL] [Abstract][Full Text] [Related]
24. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.
Choy EH; Hoogendijk JE; Lecky B; Winer JB
Cochrane Database Syst Rev; 2005 Jul; (3):CD003643. PubMed ID: 16034905
[TBL] [Abstract][Full Text] [Related]
25. Influenza A H1N1/2009 vaccine in juvenile dermatomyositis: reduced immunogenicity in patients under immunosuppressive therapy.
Guissa VR; Pereira RM; Sallum AM; Aikawa NE; Campos LM; Silva CA; Bonfá E
Clin Exp Rheumatol; 2012; 30(4):583-8. PubMed ID: 22931582
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
[TBL] [Abstract][Full Text] [Related]
27. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
28. Medications received by patients with juvenile dermatomyositis.
Kishi T; Bayat N; Ward MM; Huber AM; Wu L; Mamyrova G; Targoff IN; Warren-Hicks WJ; Miller FW; Rider LG;
Semin Arthritis Rheum; 2018 Dec; 48(3):513-522. PubMed ID: 29773230
[TBL] [Abstract][Full Text] [Related]
29. Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.
Leung AKC; Lam JM; Alobaida S; Leong KF; Wong AHC
Curr Pediatr Rev; 2021; 17(4):273-287. PubMed ID: 33902423
[TBL] [Abstract][Full Text] [Related]
30. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
[TBL] [Abstract][Full Text] [Related]
31. Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone.
Fischer TJ; Rachelefsky GS; Klein RB; Paulus HE; Stiehm ER
Am J Dis Child; 1979 Apr; 133(4):386-9. PubMed ID: 433855
[TBL] [Abstract][Full Text] [Related]
32. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
[TBL] [Abstract][Full Text] [Related]
33. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
34. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
[TBL] [Abstract][Full Text] [Related]
35. Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers.
Varnier GC; Consolaro A; Maillard S; Pilkington C; Ravelli A
Rheumatology (Oxford); 2021 Nov; 60(11):5419-5423. PubMed ID: 33528490
[TBL] [Abstract][Full Text] [Related]
36. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
37. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
38. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
[TBL] [Abstract][Full Text] [Related]
39. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.
Herfarth H; Barnes EL; Valentine JF; Hanson J; Higgins PDR; Isaacs KL; Jackson S; Osterman MT; Anton K; Ivanova A; Long MD; Martin C; Sandler RS; Abraham B; Cross RK; Dryden G; Fischer M; Harlan W; Levy C; McCabe R; Polyak S; Saha S; Williams E; Yajnik V; Serrano J; Sands BE; Lewis JD;
Gastroenterology; 2018 Oct; 155(4):1098-1108.e9. PubMed ID: 29964043
[TBL] [Abstract][Full Text] [Related]
40. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
